Clinical Obesity最新文献_第5页

IF 2.1

Clinical Obesity Pub Date : 2026-05-18

引用次数: 0

IF 2.1

Clinical Obesity Pub Date : 2026-05-12

引用次数: 0

IF 2.1

Clinical Obesity Pub Date : 2026-05-05

引用次数: 0

IF 2.1

Clinical Obesity Pub Date : 2026-05-04

引用次数: 0

IF 2.1

Clinical Obesity Pub Date : 2026-05-03

引用次数: 0

IF 2.1

Clinical Obesity Pub Date : 2026-05-03

引用次数: 0

Exploratory Analysis of Liraglutide Effects on Obstructive Sleep Apnea and Health-Related Quality of Life in Individuals With Obesity and COPD: A Secondary Analysis of a Randomised Controlled Trial 利拉鲁肽对肥胖和COPD患者阻塞性睡眠呼吸暂停和健康相关生活质量影响的探索性分析：一项随机对照试验的二次分析

IF 2.1

Clinical Obesity Pub Date : 2026-03-23 DOI: 10.1111/cob.70079

Sofie Krogh Wolsing, Ayse Dudu Altintas Dogan, Claus Bogh Juhl, Søren Hess, Torben Tranborg Jensen, Else-Marie Bladbjerg, Ole Hilberg

{"title":"Exploratory Analysis of Liraglutide Effects on Obstructive Sleep Apnea and Health-Related Quality of Life in Individuals With Obesity and COPD: A Secondary Analysis of a Randomised Controlled Trial","authors":"Sofie Krogh Wolsing, Ayse Dudu Altintas Dogan, Claus Bogh Juhl, Søren Hess, Torben Tranborg Jensen, Else-Marie Bladbjerg, Ole Hilberg","doi":"10.1111/cob.70079","DOIUrl":"10.1111/cob.70079","url":null,"abstract":"Obstructive sleep apnea (OSA) is associated with chronic obstructive pulmonary disease (COPD) and obesity, and all three are linked to reduced health-related quality of life (HRQoL). Coexistence of OSA and COPD increases morbidity and mortality compared to each condition alone. Liraglutide, a glucagon-like peptide 1 receptor agonist, may influence respiratory and HRQoL outcomes. In this secondary exploratory analysis of a randomised controlled trial including individuals with overweight or obesity and COPD, we evaluated effects of liraglutide on OSA prevalence and severity, daytime sleepiness (Epworth Sleepiness Scale, ESS), and HRQoL (Short Form-36 version 2, SF-36v2). In a double-blinded randomised controlled trial, 40 participants with overweight or obesity and COPD from two outpatient clinics were randomised to liraglutide (3.0 mg, subcutaneous) or placebo for 40 weeks. Cardiorespiratory monitoring, SF-36v2 and ESS questionnaires were conducted at baseline and end of treatment. OSA was diagnosed in 84% of participants (70% in the liraglutide group and 85% in the placebo group). Compared to placebo, liraglutide significantly reduced OSA severity, with mean baseline-adjusted differences of −9.87 events/h (β 95% CI −19.5; −0.247, p = 0.044) in Apnea–Hypopnea Index and −10.16 events/h (β 95% CI −19.29; −1.03, p = 0.029) in Oxygen Desaturation Index. ESS scores did not change significantly. Significant improvements were observed in the SF-36v2 subdomains General Health Perception and Role Physical. OSA is common among individuals with overweight or obesity and COPD. Forty weeks of liraglutide treatment were associated with reduced OSA severity and improvements in selected HRQoL domains in this population.","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 2","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13008477/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147503377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Severe Obesity Management in a Large Academic Health System: A Retrospective Evaluation of Metabolic Bariatric Surgery Counselling Practices 大型学术卫生系统中的严重肥胖管理：对代谢减肥手术咨询实践的回顾性评估。

IF 2.1

Clinical Obesity Pub Date : 2026-03-23 DOI: 10.1111/cob.70077

Mustafa Naveed, Elizabeth Gienger, Tonja Locklear, Amy Frazier, Robert Carpenter

{"title":"Severe Obesity Management in a Large Academic Health System: A Retrospective Evaluation of Metabolic Bariatric Surgery Counselling Practices","authors":"Mustafa Naveed, Elizabeth Gienger, Tonja Locklear, Amy Frazier, Robert Carpenter","doi":"10.1111/cob.70077","DOIUrl":"10.1111/cob.70077","url":null,"abstract":"<div>\u0000 \u0000 Metabolic and bariatric surgery (MBS) is an effective treatment for severe obesity but remains substantially underutilized. Limited data exist on outpatient counselling patterns preceding surgical uptake. Using electronic health record data, we conducted a 10-year retrospective cohort study of adults with body mass index ≥ 40 kg/m2. The primary outcome was documentation of the MBS discussion. Secondary outcomes included MBS receipt and demographic factors associated with documented discussion. Among 60 574 eligible patients, only 7.6% had documented MBS discussion. Overall, 1.2% underwent MBS. Surgery occurred in 12.1% of patients with documented discussion compared with 0.3% without discussion. Patients with documented discussion were younger (median, 42 vs. 47 years), had higher BMI (median, 46.8 vs. 42.0 kg/m2), and were more often female. Eligible women were more likely than men to have documented discussion (8.7% vs. 5.5%). Black patients had higher discussion rates than White patients, despite known downstream disparities in MBS utilization. Documented MBS discussion is rare but represents a critical inflection point in surgical uptake. Demographic differences in counselling suggest clinician- and system-level factors influence access before referral, highlighting outpatient counselling as a key target to improve equitable MBS utilization.\u0000 </div>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 2","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147503422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Misconceptions About Obesity and Weight Stigma in Brazilian Healthcare Professionals 巴西医疗保健专业人员对肥胖和体重污名的误解

IF 2.1

Clinical Obesity Pub Date : 2026-03-18 DOI: 10.1111/cob.70074

Paula Victoria Sozza, Eva Penelo, Stuart William Flint, David Sánchez-Carracedo, Sebastião Sousa Almeida, Telma Maria Braga Costa, Maria Fernanda Laus

{"title":"Misconceptions About Obesity and Weight Stigma in Brazilian Healthcare Professionals","authors":"Paula Victoria Sozza, Eva Penelo, Stuart William Flint, David Sánchez-Carracedo, Sebastião Sousa Almeida, Telma Maria Braga Costa, Maria Fernanda Laus","doi":"10.1111/cob.70074","DOIUrl":"10.1111/cob.70074","url":null,"abstract":"People living with obesity (PLWO) frequently experience weight stigma (WS) in healthcare settings, leading to disparities in treatment. Although research shows that healthcare professionals (HCPs) often hold stigmatising views, this issue remains underexplored in Brazil. The objective of this study is to examine WS and beliefs about obesity amongst Brazilian HCPs. Five hundred seven Brazilian HCPs completed a survey assessing sociodemographic data, beliefs about obesity and the Fat Phobia Scale-Short Form (FPS-SF) for assessing WS. Linear regression models analysed the association between these variables. HCPs who are men (p = 0.007) and physicians (p < 0.001) had significantly higher WS. Participants who attributed overeating to physiological dysfunction (p = 0.004) or the food environment (p = 0.020) reported significantly lower WS compared to those who attributed it to emotional eating. Those who attributed weight loss difficulty to genetic or metabolic factors (p < 0.001) had significantly lower WS compared to those that reported lack of motivation or self-discipline. People who reported a belief that there are factors beyond patients' control (p = 0.001), inadequate care by HCP (p = 0.018) or biological mechanisms (p = 0.007) that prevent weight loss reported significantly lower WS compared to HCPs who believe it's the result of a lack of motivation/self-discipline. In conclusion, higher levels of WS were observed in HCPs who are men, physicians and HCPs who attribute the causes and management of obesity to personal responsibility. These findings emphasise the need for interventions to address WS in HCPs and to improve care for PLWO.","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 2","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12999358/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147479956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of Semaglutide and Lifestyle Counselling for Weight Loss Using Multi-Site Electronic Health Records 使用多站点电子健康记录进行西马鲁肽和生活方式减肥咨询的比较

IF 2.1

Clinical Obesity Pub Date : 2026-03-13 DOI: 10.1111/cob.70076

William J. B. Powell, Diego R. Mazzotti, Stephen D. Herrmann, Ann M. Davis, Bettina Mittendorfer, Jared Bruce, Xing Song, Lemuel R. Waitman

{"title":"Comparison of Semaglutide and Lifestyle Counselling for Weight Loss Using Multi-Site Electronic Health Records","authors":"William J. B. Powell, Diego R. Mazzotti, Stephen D. Herrmann, Ann M. Davis, Bettina Mittendorfer, Jared Bruce, Xing Song, Lemuel R. Waitman","doi":"10.1111/cob.70076","DOIUrl":"10.1111/cob.70076","url":null,"abstract":"<div>\u0000 \u0000 To evaluate the effectiveness of semaglutide compared with lifestyle counselling alone for weight loss in diabetic and non-diabetic patients with obesity. This multi-site, retrospective, observational study uses data from electronic health records which are part of the Greater Plains Collaborative (GPC) in a time-to-event analysis for comparative effectiveness. Participants were adults with obesity receiving semaglutide for a minimum of 16 weeks or lifestyle counselling with at least three sessions within the first 16 weeks. The primary outcome is incidence of 10% or greater reduction in weight from baseline. Of 3927 eligible participants, 615 were prescribed semaglutide and 3312 received lifestyle counselling. Following propensity score matching, each group (diabetic and non-diabetic) consisted of 120 and 495 participants, respectively. Hazard ratios for 10% weight loss were significantly higher from semaglutide for non-diabetic (1.63 [95% CI: 1.32, 2.01; p < 0.001]) and diabetic (2.45 [95% CI: 1.47, 4.09; p < 0.001]) populations. These data from our study suggest that semaglutide therapy compared with lifestyle counselling alone is more effective in achieving at least 10% weight loss. This information may be used to inform clinical practice guidelines and stimulate future research on the long-term effectiveness of various weight loss options for individuals with obesity.\u0000 </div>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 2","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147456090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0